All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

A Brief Note on Childhood Acute Lymphoblastic Leukemia

Sterling Kain*

Department of Oncology, University of Cambridge, Cambridge, United Kingdom

*Corresponding Author:
Sterling Kain
Department of Oncology,
University of Cambridge,
United Kingdom

Received: 7-Feb-2022 Manuscript No. MCO-22- 52478; Editor assigned: 9-Feb-2022, Pre QC No. MCO-22- 52478 (PQ); Reviewed: 23-Feb-2022, QC No. JZS-22- 52478; Accepted: 25-Feb-2022, Manuscript No. MCO-22- 52478 (A); Published: 04-Mar-2022, DOI: 10.4172/ Med & Clin Oncol.6.1.001

Visit for more related articles at Research & Reviews: Medical and Clinical Oncology


Childhood Acute Lymphoblastic Leukemia (ALL) is a kind of cancer in which the bone marrow produces an excessive number of immature lymphocytes in children (a type of white blood cell). Leukemia can impact red blood cells, white blood cells, and platelets. Childhood Acute Lymphoblastic Leukemia risk is influenced by previous cancer therapy and specific genetic factors. Fever and bruising are common childhood symptoms. Childhood Acute Lymphoblastic Leukemia is diagnosed with tests that look at the blood and bone marrow. The prognosis and treatment options are influenced by a number of factors.

The bone marrow of a healthy child produces blood stem cells (immature cells) that mature into mature blood cells throughout time. A blood stem cell can differentiate into a myeloid or lymphoid stem cell. A large number of stem cells differentiate into lymphoblasts, B lymphocytes or T lymphocytes. Leukemia cells are another name for these cells. These leukaemia cells do not function like normal lymphocytes and are unable to effectively fight infection. In addition, when the number of leukaemia cells in the blood and bone marrow rises, there is less room in the blood and bone marrow for healthy white blood cells, red blood cells, and platelets. Infection, anemia and simple bleeding are the possible outcomes.

The viable risk factors for childhood Acute Lymphoblastic Leukemia are being exposed to x-rays before birth. Other signs and symptoms include fever, Petechiae (flat, pinpoint, dark-red spots under the skin caused by bleeding), weakness, fatigue or pale appearance. Below the ribs, there is a feeling of fullness. Appetite loss is common.

In childhood Acute Lymphoblastic Leukemia, there are three risk groups. The typical low risk comprises of children aged one to ten years old who seem to have a white blood cell count of fewer than 50,000 cells per litre at the time of diagnosis. The second is high risk, which is defined as having a white blood cell count of 50,000/L or above at the time of diagnosis. The third group includes infants under the age of one, children with particular genetic mutations, children who have a slow reaction to early treatment, and children who show indications of leukaemia during the first four weeks of treatment.

Other factors include whether the leukaemia cells originated from B lymphocytes or T lymphocytes, as well as any changes in the lymphocytes' chromosomes or genes, how quickly the leukaemia cell count drops after treatment, and whether leukemia cells are found in the cerebrospinal fluid at the time of testing. Acute lymphoblastic leukaemia in children can be treated in different ways. Chemotherapy, radiation therapy, chemotherapy with stem cell transplant, and targeted therapy are the four basic treatments.

The following are some of the long-term impacts of cancer treatment. Physical issues are such as heart, blood vessel, liver or bone disorders, as well as infertility. The risk of late cardiac damage is reduced when dexrazoxane is taken alongside chemotherapy medicines known as anthracyclines. These consequences are more likely in children under the age of four who have had brain radiation therapy. Brain tumours, thyroid cancer, acute myeloid leukaemia, and myelodysplastic syndrome are examples of second malignancies (new forms of cancer).

Participating in a research study could be the best therapeutic option for some patients. Clinical trials are an important aspect of cancer research. Clinical trials are conducted to determine whether novel cancer treatments are safe, effective, or superior to current treatments. Many of today's mainstream cancer treatments are based on previous clinical studies. Patients who participate in a clinical study may receive routine care or be the first one to receive a novel treatment. Patients who participate in clinical trials contribute to the advancement of cancer treatment in the future. Even if clinical trials may not result in novel medicines that are effective, they frequently answer critical questions and advance research.